1
|
Chosy MB, Sun J, Rahn HP, Liu X, Brčić J, Wender PA, Cegelski L. Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-Associated S. aureus. ACS Infect Dis 2024; 10:384-397. [PMID: 38252999 DOI: 10.1021/acsinfecdis.3c00168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
The global challenge of antibiotic resistance necessitates the introduction of more effective antibiotics. Here we report a potentially general design strategy, exemplified with vancomycin, that improves and expands antibiotic performance. Vancomycin is one of the most important antibiotics in use today for the treatment of Gram-positive infections. However, it fails to eradicate difficult-to-treat biofilm populations. Vancomycin is also ineffective in killing Gram-negative bacteria due to its inability to breach the outer membrane. Inspired by our seminal studies on cell penetrating guanidinium-rich transporters (e.g., octaarginine), we recently introduced vancomycin conjugates that effectively eradicate Gram-positive biofilm bacteria, persister cells and vancomycin-resistant enterococci (with V-r8, vancomycin-octaarginine), and Gram-negative pathogens (with V-R, vancomycin-arginine). Having shown previously that the spatial array (linear versus dendrimeric) of multiple guanidinium groups affects cell permeation, we report here for the first time vancomycin conjugates with dendrimerically displayed guanidinium groups that exhibit superior efficacy and breadth, presenting the best activity of V-r8 and V-R in single broad-spectrum compounds active against ESKAPE pathogens. Mode-of-action studies reveal cell-surface activity and enhanced vancomycin-like killing. The vancomycin-polyguanidino dendrimer conjugates exhibit no acute mammalian cell toxicity or hemolytic activity. Our study introduces a new class of broad-spectrum vancomycin derivatives and a general strategy to improve or expand antibiotic performance through combined mode-of-action and function-oriented design studies.
Collapse
Affiliation(s)
- Madeline B Chosy
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jiuzhi Sun
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Harrison P Rahn
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Xinyu Liu
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jasna Brčić
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Lynette Cegelski
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
2
|
Shanmukha S, Godfrey WH, Gharibani P, Lee JJ, Guo Y, Deng X, Wender PA, Kornberg MD, Kim PM. TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis. bioRxiv 2024:2024.02.02.578637. [PMID: 38370818 PMCID: PMC10871289 DOI: 10.1101/2024.02.02.578637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Protein kinase C (PKC) plays a key role in modulating the activities of the innate immune cells of the central nervous system (CNS). A delicate balance between pro-inflammatory and regenerative activities by microglia and CNS-associated macrophages is necessary for the proper functioning of the CNS. Thus, a maladaptive activation of these CNS innate immune cells results in neurodegeneration and demyelination associated with various neurologic disorders, such as multiple sclerosis (MS) and Alzheimer's disease. Prior studies have demonstrated that modulation of PKC activity by bryostatin-1 (bryo-1) and its analogs (bryologs) attenuates the pro-inflammatory processes by microglia/CNS macrophages and alleviates the neurologic symptoms in experimental autoimmune encephalomyelitis (EAE), an MS animal model. Here, we demonstrate that (2S,5S)-(E,E)-8-(5-(4(trifluoromethyl)phenyl)-2,4-pentadienoylamino)benzolactam (TPPB), a structurally distinct PKC modulator, has a similar effect to bryo-1 on CNS innate immune cells both in vitro and in vivo, attenuating neuroinflammation and resulting in CNS regeneration and repair. This study identifies a new structural class of PKC modulators, which can therapeutically target CNS innate immunity as a strategy to treat neuroinflammatory and neurodegenerative disorders.
Collapse
Affiliation(s)
- Shruthi Shanmukha
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| | - Wesley H. Godfrey
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| | - Payam Gharibani
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| | - Judy J. Lee
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| | - Yu Guo
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine; Baltimore, Maryland, 21287, USA
| | - Xiaojing Deng
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| | - Paul A. Wender
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, California, 94305, USA
| | - Michael D. Kornberg
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| | - Paul M. Kim
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
| |
Collapse
|
3
|
Blazkova J, Whitehead EJ, Schneck R, Shi V, Justement JS, Rai MA, Kennedy BD, Manning MR, Praiss L, Gittens K, Wender PA, Oguz C, Lack J, Moir S, Chun TW. Immunologic and virologic parameters associated with HIV DNA reservoir size in people living with HIV receiving antiretroviral therapy. J Infect Dis 2023:jiad595. [PMID: 38128541 DOI: 10.1093/infdis/jiad595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 12/12/2023] [Accepted: 12/19/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND A better understanding of the dynamics of HIV reservoirs in CD4+ T cells of people with HIV (PWH) receiving antiretroviral therapy (ART) is crucial for developing therapies to eradicate the virus. METHODS We conducted a study involving 28 aviremic PWH receiving ART with high and low levels of HIV DNA. We analyzed immunologic and virologic parameters and their association with the HIV reservoir size. RESULTS The frequency of CD4+ T cells carrying HIV DNA was associated with higher pre-ART plasma viremia, lower pre-ART CD4+ T cell counts, and lower pre-ART CD4/CD8 ratios. During ART, the High group maintained elevated levels of intact HIV proviral DNA, cell-associated HIV RNA, and inducible virion-associated HIV RNA. HIV sequence analysis showed no evidence for preferential accumulation of defective proviruses nor higher frequencies of clonal expansion in the High versus Low group. Phenotypic and functional T-cell analyses did not show enhanced immune-mediated virologic control in the Low versus High group. Of considerable interest, pre-ART innate immunity was significantly higher in the Low versus High group. CONCLUSIONS Our data suggest that innate immunity at the time of ART initiation may play an important role in modulating the dynamics and persistence of viral reservoirs in PWH.
Collapse
Affiliation(s)
- Jana Blazkova
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Emily J Whitehead
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Rachel Schneck
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Victoria Shi
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - J Shawn Justement
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - M Ali Rai
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Brooke D Kennedy
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Maegan R Manning
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Lauren Praiss
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Kathleen Gittens
- Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, USA
| | - Paul A Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, CA, USA
| | - Cihan Oguz
- Integrated Data Sciences Section, Research Technologies Branch, NIAID, NIH, Bethesda, MD, USA
| | - Justin Lack
- Integrated Data Sciences Section, Research Technologies Branch, NIAID, NIH, Bethesda, MD, USA
| | - Susan Moir
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Tae-Wook Chun
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| |
Collapse
|
4
|
Li Z, Amaya L, Pi R, Wang SK, Ranjan A, Waymouth RM, Blish CA, Chang HY, Wender PA. Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism. Nat Commun 2023; 14:6983. [PMID: 37914693 PMCID: PMC10620205 DOI: 10.1038/s41467-023-42672-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 10/18/2023] [Indexed: 11/03/2023] Open
Abstract
The introduction of more effective and selective mRNA delivery systems is required for the advancement of many emerging biomedical technologies including the development of prophylactic and therapeutic vaccines, immunotherapies for cancer and strategies for genome editing. While polymers and oligomers have served as promising mRNA delivery systems, their efficacy in hard-to-transfect cells such as primary T lymphocytes is often limited as is their cell and organ tropism. To address these problems, considerable attention has been placed on structural screening of various lipid and cation components of mRNA delivery systems. Here, we disclose a class of charge-altering releasable transporters (CARTs) that differ from previous CARTs based on their beta-amido carbonate backbone (bAC) and side chain spacing. These bAC-CARTs exhibit enhanced mRNA transfection in primary T lymphocytes in vitro and enhanced protein expression in vivo with highly selective spleen tropism, supporting their broader therapeutic use as effective polyanionic delivery systems.
Collapse
Affiliation(s)
- Zhijian Li
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA
| | - Laura Amaya
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, 94305, USA
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Ruoxi Pi
- Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford, CA, 94305, USA
| | - Sean K Wang
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, 94305, USA
- Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, 94305, USA
| | - Alok Ranjan
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA
| | - Robert M Waymouth
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA
| | - Catherine A Blish
- Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford, CA, 94305, USA
- Chan Zuckerberg Biohub, San Francisco, CA, USA
| | - Howard Y Chang
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, 94305, USA
- Howard Hughes Medical Institute, Stanford University, Stanford, CA, 94305, USA
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA.
- Department of Chemical and Systems Biology, Stanford University, Stanford, CA, 94305, USA.
| |
Collapse
|
5
|
Brčić J, Tong A, Wender PA, Cegelski L. Conjugation of Vancomycin with a Single Arginine Improves Efficacy against Mycobacteria by More Effective Peptidoglycan Targeting. J Med Chem 2023; 66:10226-10237. [PMID: 37477249 PMCID: PMC10783851 DOI: 10.1021/acs.jmedchem.3c00565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/22/2023]
Abstract
Drug resistant bacterial infections have emerged as one of the greatest threats to public health. The discovery and development of new antimicrobials and anti-infective strategies are urgently needed to address this challenge. Vancomycin is one of the most important antibiotics for the treatment of Gram-positive infections. Here, we introduce the vancomycin-arginine conjugate (V-R) as a highly effective antimicrobial against actively growing mycobacteria and difficult-to-treat mycobacterial biofilm populations. Further improvement in efficacy through combination treatment of V-R to inhibit peptidoglycan synthesis and ethambutol to inhibit arabinogalactan synthesis underscores the ability to identify compound synergies to more effectively target the Achilles heel of the cell-wall assembly. Moreover, we introduce mechanistic activity data and a molecular model derived from a d-Ala-d-Ala-bound vancomycin structure that we hypothesize underlies the molecular basis for the antibacterial improvement attributed to the arginine modification that is specific to peptidoglycan chemistry employed by mycobacteria and distinct from Gram-positive pathogens.
Collapse
Affiliation(s)
- Jasna Brčić
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | - Alan Tong
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
- Department of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA
| | - Lynette Cegelski
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| |
Collapse
|
6
|
Werby SH, Brčić J, Chosy MB, Sun J, Rendell JT, Neville LF, Wender PA, Cegelski L. Detection of intact vancomycin-arginine as the active antibacterial conjugate in E. coli by whole-cell solid-state NMR. RSC Med Chem 2023; 14:1192-1198. [PMID: 37360389 PMCID: PMC10285746 DOI: 10.1039/d3md00173c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 05/13/2023] [Indexed: 06/28/2023] Open
Abstract
The introduction of new and improved antibacterial agents based on facile synthetic modifications of existing antibiotics represents a promising strategy to deliver urgently needed antibacterial candidates to treat multi-drug resistant bacterial infections. Using this strategy, vancomycin was transformed into a highly active agent against antibiotic-resistant Gram-negative organisms in vitro and in vivo through the addition of a single arginine to yield vancomycin-arginine (V-R). Here, we report detection of the accumulation of V-R in E. coli by whole-cell solid-state NMR using 15N-labeled V-R. 15N CPMAS NMR revealed that the conjugate remained fully amidated without loss of arginine, demonstrating that intact V-R represents the active antibacterial agent. Furthermore, C{N}REDOR NMR in whole cells with all carbons at natural abundance 13C levels exhibited the sensitivity and selectivity to detect the directly bonded 13C-15N pairs of V-R within E. coli cells. Thus, we also present an effective methodology to directly detect and evaluate active drug agents and their accumulation within bacteria without the need for potentially perturbative cell lysis and analysis protocols.
Collapse
Affiliation(s)
- Sabrina H Werby
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | - Jasna Brčić
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | - Madeline B Chosy
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | - Jiuzhi Sun
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | | | | | - Paul A Wender
- Department of Chemistry, Stanford University Stanford CA 94305 USA
- Department of Chemical and Systems Biology, Stanford University Stanford CA 94305 USA
| | - Lynette Cegelski
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| |
Collapse
|
7
|
Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, Chang HY. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci U S A 2023; 120:e2302191120. [PMID: 37155869 PMCID: PMC10193964 DOI: 10.1073/pnas.2302191120] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Accepted: 04/14/2023] [Indexed: 05/10/2023] Open
Abstract
Circular RNAs (circRNAs) are a class of RNAs commonly found across eukaryotes and viruses, characterized by their resistance to exonuclease-mediated degradation. Their superior stability compared to linear RNAs, combined with previous work showing that engineered circRNAs serve as efficient protein translation templates, make circRNA a promising candidate for RNA medicine. Here, we systematically examine the adjuvant activity, route of administration, and antigen-specific immunity of circRNA vaccination in mice. Potent circRNA adjuvant activity is associated with RNA uptake and activation of myeloid cells in the draining lymph nodes and transient cytokine release. Immunization of mice with engineered circRNA encoding a protein antigen delivered by a charge-altering releasable transporter induced innate activation of dendritic cells, robust antigen-specific CD8 T cell responses in lymph nodes and tissues, and strong antitumor efficacy as a therapeutic cancer vaccine. These results highlight the potential utility of circRNA vaccines for stimulating potent innate and T cell responses in tissues.
Collapse
Affiliation(s)
- Laura Amaya
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA94305
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA94305
| | - Lilit Grigoryan
- Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA94305
| | - Zhijian Li
- Department of Chemistry, Stanford University, Stanford, CA94305
| | - Audrey Lee
- Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA94305
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, CA94305
- Department of Chemical and Systems Biology, Stanford University, Stanford, CA94305
| | - Bali Pulendran
- Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA94305
| | - Howard Y. Chang
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA94305
- HHMI, Stanford University, Stanford, CA94305
| |
Collapse
|
8
|
Moran JA, Ranjan A, Hourani R, Kim JT, Wender PA, Zack JA, Marsden MD. Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal. Virology 2023; 581:8-14. [PMID: 36842270 PMCID: PMC10103183 DOI: 10.1016/j.virol.2023.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 02/01/2023] [Accepted: 02/15/2023] [Indexed: 02/18/2023]
Abstract
HIV can establish a long-lived latent infection in cells harboring integrated non-expressing proviruses. Latency reversing agents (LRAs), including protein kinase C (PKC) modulators, can induce expression of latent HIV, thereby reducing the latent reservoir in animal models. However, PKC modulators such as bryostatin-1 also cause cytokine upregulation in peripheral blood mononuclear cells (PBMCs), including cytokines that might independently reverse HIV latency. To determine whether cytokines induced by PKC modulators contribute to latency reversal, primary human PBMCs were treated with bryostatin-1 or the bryostatin analog SUW133, a superior LRA, and supernatant was collected. As anticipated, LRA-treated cell supernatant contained increased levels of cytokines compared to untreated cell supernatant. However, exposure of latently-infected cells with this supernatant did not result in latency reactivation. These results indicate that PKC modulators do not have significant indirect effects on HIV latency reversal in vitro and thus are targeted in their latency reversing ability.
Collapse
Affiliation(s)
- Jose A Moran
- Department of Microbiology and Molecular Genetics, School of Medicine, University of California Irvine, CA, 92697, USA
| | - Alok Ranjan
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA; Department of Systems and Chemical Biology, Stanford University, Stanford, CA, 94305, USA
| | - Rami Hourani
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA; Department of Systems and Chemical Biology, Stanford University, Stanford, CA, 94305, USA
| | - Jocelyn T Kim
- Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, CA, 94305, USA; Department of Systems and Chemical Biology, Stanford University, Stanford, CA, 94305, USA
| | - Jerome A Zack
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA; Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Matthew D Marsden
- Department of Microbiology and Molecular Genetics, School of Medicine, University of California Irvine, CA, 92697, USA; Department of Medicine (Division of Infectious Diseases), School of Medicine, University of California Irvine, CA, 92697, USA.
| |
Collapse
|
9
|
Blake TR, Haabeth OAW, Sallets A, McClellan RL, Del Castillo TJ, Vilches-Moure JG, Ho WC, Wender PA, Levy R, Waymouth RM. Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs. Bioconjug Chem 2023:10.1021/acs.bioconjchem.3c00019. [PMID: 36996808 PMCID: PMC10601965 DOI: 10.1021/acs.bioconjchem.3c00019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/01/2023]
Abstract
Targeted delivery of nucleic acid therapeutics to the lungs could transform treatment options for pulmonary disease. We have previously developed oligomeric charge-altering releasable transporters (CARTs) for in vivo mRNA transfection and demonstrated their efficacy for use in mRNA-based cancer vaccination and local immunomodulatory therapies against murine tumors. While our previously reported glycine-based CART-mRNA complexes (G-CARTs/mRNA) show selective protein expression in the spleen (mouse, >99%), here, we report a new lysine-derived CART-mRNA complex (K-CART/mRNA) that, without additives or targeting ligands, shows selective protein expression in the lungs (mouse, >90%) following systemic IV administration. We further show that by delivering siRNA using the K-CART, we can significantly decrease expression of a lung-localized reporter protein. Blood chemistry and organ pathology studies demonstrate that K-CARTs are safe and well-tolerated. We report on the new step economical, organocatalytic synthesis (two steps) of functionalized polyesters and oligo-carbonate-co-α-aminoester K-CARTs from simple amino acid and lipid-based monomers. The ability to direct protein expression selectively in the spleen or lungs by simple, modular changes to the CART structure opens fundamentally new opportunities in research and gene therapy.
Collapse
Affiliation(s)
- Timothy R Blake
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Ole A W Haabeth
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States
| | - Adrienne Sallets
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States
| | - Rebecca L McClellan
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Trevor J Del Castillo
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jose G Vilches-Moure
- Department of Comparative Medicine, Stanford University, Stanford, California 94305, United States
| | - Wilson C Ho
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Ronald Levy
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States
| | - Robert M Waymouth
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
10
|
Kennedy BD, Blazkova J, Justement JS, Shi V, Rai MA, Manning MR, Praiss L, Gittens K, Wender PA, Patro S, Wu X, Moir S, Chun TW. Comprehensive analysis of HIV reservoirs in elite controllers. J Clin Invest 2023; 133:e165446. [PMID: 36719383 PMCID: PMC9888367 DOI: 10.1172/jci165446] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Affiliation(s)
- Brooke D. Kennedy
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - Jana Blazkova
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - Jesse S. Justement
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - Victoria Shi
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - M. Ali Rai
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - Maegan R. Manning
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - Lauren Praiss
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | | | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, California, USA
| | - Sean Patro
- Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
| | - Xiaolin Wu
- Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
| | - Susan Moir
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| | - Tae-Wook Chun
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, and
| |
Collapse
|
11
|
Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA, Chang HY. Engineering circular RNA for enhanced protein production. Nat Biotechnol 2023; 41:262-272. [PMID: 35851375 PMCID: PMC9931579 DOI: 10.1038/s41587-022-01393-0] [Citation(s) in RCA: 66] [Impact Index Per Article: 66.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 06/14/2022] [Indexed: 01/07/2023]
Abstract
Circular RNAs (circRNAs) are stable and prevalent RNAs in eukaryotic cells that arise from back-splicing. Synthetic circRNAs and some endogenous circRNAs can encode proteins, raising the promise of circRNA as a platform for gene expression. In this study, we developed a systematic approach for rapid assembly and testing of features that affect protein production from synthetic circRNAs. To maximize circRNA translation, we optimized five elements: vector topology, 5' and 3' untranslated regions, internal ribosome entry sites and synthetic aptamers recruiting translation initiation machinery. Together, these design principles improve circRNA protein yields by several hundred-fold, provide increased translation over messenger RNA in vitro, provide more durable translation in vivo and are generalizable across multiple transgenes.
Collapse
Affiliation(s)
- Robert Chen
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA
| | - Sean K Wang
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.,Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA
| | - Julia A Belk
- Department of Computer Science, Stanford University, Stanford, CA, USA
| | - Laura Amaya
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA
| | - Zhijian Li
- Department of Chemistry, Stanford University, Stanford, CA, USA
| | - Angel Cardenas
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA
| | - Brian T Abe
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA
| | - Chun-Kan Chen
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, CA, USA.,Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA
| | - Howard Y Chang
- Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA. .,Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
| |
Collapse
|
12
|
Wender PA, Luu-Nguyen QH, Sloane JL, Ranjan A. Trimethylene Methane Dianion Equivalent for the Asymmetric Consecutive Allylation of Aldehydes: Applications to Prins-Driven Macrocyclizations for the Synthesis of Bryostatin 1 and Analogues. J Org Chem 2022; 87:15925-15937. [PMID: 36378802 DOI: 10.1021/acs.joc.2c02047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We report a one-step (one-flask) generation and reaction of a bifunctional allylating reagent, a trimethylene methane dianion equivalent, that provides a route for the asymmetric 2-(trimethylsilylmethyl) allylation of aldehydes. The product of the first aldehyde allylation process is then set to engage in a second separate aldehyde allylation, providing an improved Prins macrocyclization strategy both for the scalable synthesis of bryostatin 1 and for the total synthesis of a new potent bryostatin analogue.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States.,Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Quang H Luu-Nguyen
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jack L Sloane
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Alok Ranjan
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
13
|
Wender PA, Gentry ZO, Fanelli DJ, Luu-Nguyen QH, McAteer OD, Njoo E. Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues. Nat Chem 2022; 14:1421-1426. [PMID: 36192432 PMCID: PMC10079359 DOI: 10.1038/s41557-022-01048-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Accepted: 08/26/2022] [Indexed: 01/04/2023]
Abstract
Tigilanol tiglate is a natural product diterpenoid in clinical trials for the treatment of a broad range of cancers. Its unprecedented protein kinase C isoform selectivity make it and its analogues exceptional leads for PKC-related clinical indications, which include human immunodeficiency virus and AIDS eradication, antigen-enhanced cancer immunotherapy, Alzheimer's disease and multiple sclerosis. Currently, the only source of tigilanol tiglate is a rain forest tree, Fontainea picrosperma, whose limited number and restricted distribution (northeastern Australia) has prompted consideration of designed tree plantations to address supply needs. Here we report a practical laboratory synthesis of tigilanol tiglate that proceeds in 12 steps (12% overall yield, >80% average yield per step) and can be used to sustainably supply tigilanol tiglate and its analogues, the latter otherwise inaccessible from the natural source. The success of this synthesis is based on a unique strategy for the installation of an oxidation pattern common to many biologically active tiglianes, daphnanes and their analogues.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Stanford University, Stanford, CA, USA.
- Department of Systems and Chemical Biology, Stanford University, Stanford, CA, USA.
| | | | - David J Fanelli
- Department of Chemistry, Stanford University, Stanford, CA, USA
| | | | - Owen D McAteer
- Department of Chemistry, Stanford University, Stanford, CA, USA
| | - Edward Njoo
- Department of Chemistry, Stanford University, Stanford, CA, USA
| |
Collapse
|
14
|
Testa S, Haabeth OAW, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, Wender PA, Waymouth RM, Levy R. Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. Biomacromolecules 2022; 23:2976-2988. [PMID: 35748182 PMCID: PMC10199726 DOI: 10.1021/acs.biomac.2c00469] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Charge-altering releasable transporters (CARTs) are a class of oligonucleotide delivery vehicles shown to be effective for delivery of messenger RNA (mRNA) both in vitro and in vivo. Here, we exploited the chemical versatility of the CART synthesis to generate CARTs containing the small-molecule drug fingolimod (FTY720) as a strategy to increase mRNA delivery and expression in lymphocytes through a specific ligand-receptor interaction. Fingolimod is an FDA-approved small-molecule drug that, upon in vivo phosphorylation, binds to the sphingosine-1-phosphate receptor 1 (S1P1), which is highly expressed on lymphocytes. Compared to its non-fingolimod-conjugated analogue, the fingolimod-conjugated CART achieved superior transfection of activated human and murine T and B lymphocytes in vitro. The higher transfection of the fingolimod-conjugated CARTs was lost when cells were exposed to a free fingolimod before transfection. In vivo, the fingolimod-conjugated CART showed increased mRNA delivery to marginal zone B cells and NK cells in the spleen, relative to CARTs lacking fingolimod. Moreover, fingolimod-CART-mediated mRNA delivery induces peripheral blood T-cell depletion similar to free fingolimod. Thus, we show that functionalization of CARTs with a pharmacologically validated small molecule can increase transfection of a cellular population of interest while conferring some of the targeting properties of the conjugated small molecule to the CARTs.
Collapse
Affiliation(s)
- Stefano Testa
- Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Ole A W Haabeth
- Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Timothy R Blake
- Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Trevor J Del Castillo
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Debra K Czerwinski
- Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Ranjani Rajapaksa
- Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Robert M Waymouth
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Ronald Levy
- Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
15
|
Kim JT, Zhang TH, Carmona C, Lee B, Seet CS, Kostelny M, Shah N, Chen H, Farrell K, Soliman MSA, Dimapasoc M, Sinani M, Blanco KYR, Bojorquez D, Jiang H, Shi Y, Du Y, Komarova NL, Wodarz D, Wender PA, Marsden MD, Sun R, Zack JA. Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nat Commun 2022; 13:121. [PMID: 35013215 PMCID: PMC8748509 DOI: 10.1038/s41467-021-27647-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 12/03/2021] [Indexed: 02/06/2023] Open
Abstract
HIV is difficult to eradicate due to the persistence of a long-lived reservoir of latently infected cells. Previous studies have shown that natural killer cells are important to inhibiting HIV infection, but it is unclear whether the administration of natural killer cells can reduce rebound viremia when anti-retroviral therapy is discontinued. Here we show the administration of allogeneic human peripheral blood natural killer cells delays viral rebound following interruption of anti-retroviral therapy in humanized mice infected with HIV-1. Utilizing genetically barcoded virus technology, we show these natural killer cells efficiently reduced viral clones rebounding from latency. Moreover, a kick and kill strategy comprised of the protein kinase C modulator and latency reversing agent SUW133 and allogeneic human peripheral blood natural killer cells during anti-retroviral therapy eliminated the viral reservoir in a subset of mice. Therefore, combinations utilizing latency reversal agents with targeted cellular killing agents may be an effective approach to eradicating the viral reservoir.
Collapse
Affiliation(s)
- Jocelyn T Kim
- Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA.
| | - Tian-Hao Zhang
- Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Camille Carmona
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Bryanna Lee
- Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Christopher S Seet
- Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Matthew Kostelny
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Nisarg Shah
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Hongying Chen
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Kylie Farrell
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Mohamed S A Soliman
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Melanie Dimapasoc
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Michelle Sinani
- Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Kenia Yazmin Reyna Blanco
- Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - David Bojorquez
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA
| | - Hong Jiang
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA
| | - Yuan Shi
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA
| | - Yushen Du
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA
| | - Natalia L Komarova
- Department of Mathematics, University of California, Irvine, Irvine, CA, 92697, USA
| | - Dominik Wodarz
- Department of Population Health and Disease Prevention, Program in Public Health Susan and Henry Samueli College of Health Sciences, University of California, Irvine, Irvine, CA, 92697, USA
| | - Paul A Wender
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, CA, 94305, USA
| | - Matthew D Marsden
- Department of Microbiology and Molecular Genetics and Department of Medicine, Division of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, CA, 92697, USA
| | - Ren Sun
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.,School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| | - Jerome A Zack
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, 90095, USA.,Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA, 90095, USA
| |
Collapse
|
16
|
Haabeth OA, Lohmeyer JJK, Sallets A, Blake TR, Sagiv-Barfi I, Czerwinski DK, McCarthy B, Powell AE, Wender PA, Waymouth RM, Levy R. An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. ACS Cent Sci 2021; 7:1191-1204. [PMID: 34341771 PMCID: PMC8265720 DOI: 10.1021/acscentsci.1c00361] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Indexed: 06/13/2023]
Abstract
The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with lipid nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a delivery vehicle called charge-altering releasable transporters (CARTs). Using these inherently nonimmunogenic vehicles, we can tailor the vaccine immunogenicity by inclusion of coformulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN). Mice vaccinated with the mRNA-CART vaccine developed therapeutically relevant levels of receptor binding domain (RBD)-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, vaccination elicited strong and long-lasting RBD-specific TH1 T cell responses including CD4+ and CD8+ T cell memory.
Collapse
Affiliation(s)
- Ole A.
W. Haabeth
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Julian J. K. Lohmeyer
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Adrienne Sallets
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Timothy R. Blake
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Idit Sagiv-Barfi
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Debra K. Czerwinski
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| | - Blaine McCarthy
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Abigail E. Powell
- Department
of Biochemistry & Stanford ChEM-H, Stanford
University, Stanford, California 94305, United States
| | - Paul A. Wender
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
- Department
of Chemical and Systems Biology, Stanford
University, Stanford, California 94305, United States
| | - Robert M. Waymouth
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Ronald Levy
- Stanford
Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
17
|
Haabeth OAW, Lohmeyer JJK, Sallets A, Blake TR, Sagiv-Barfi I, Czerwinski DK, McCarthy B, Powell AE, Wender PA, Waymouth RM, Levy R. An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory. bioRxiv 2021. [PMID: 33880472 DOI: 10.1101/2021.04.14.439891] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with Lipid Nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a delivery vehicle called Charge-Altering Releasable Transporters (CARTs). Using these inherently nonimmunogenic vehicles we can tailor the vaccine immunogenicity by inclusion of co-formulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN). Mice vaccinated with the mRNA-CART vaccine developed therapeutically relevant levels of RBD-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, vaccination elicited strong and long lasting RBD-specific T H 1 T cell responses including CD4 + and CD8 + T cell memory.
Collapse
|
18
|
Bitnun A, Ransy DG, Brophy J, Kakkar F, Hawkes M, Samson L, Annabi B, Pagliuzza A, Morand JA, Sauve L, Chomont N, Lavoie S, Kim J, Sandstrom P, Wender PA, Lee T, Singer J, Read SE, Soudeyns H. Clinical Correlates of Human Immunodeficiency Virus-1 (HIV-1) DNA and Inducible HIV-1 RNA Reservoirs in Peripheral Blood in Children With Perinatally Acquired HIV-1 Infection With Sustained Virologic Suppression for at Least 5 Years. Clin Infect Dis 2021; 70:859-866. [PMID: 30919879 DOI: 10.1093/cid/ciz251] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Accepted: 03/20/2019] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND The Early Pediatric Initiation Canada Child Cure Cohort (EPIC4) study is a prospective, multicenter, Canadian cohort study investigating human immunodeficiency virus-1 (HIV-1) reservoirs, chronic inflammation, and immune responses in children with perinatally acquired HIV-1 infection. The focus of this report is HIV-1 reservoirs and correlates in the peripheral blood of children who achieved sustained virologic suppression (SVS) for ≥5 years. METHODS HIV-1 reservoirs were determined by measuring HIV-1 DNA in peripheral blood mononuclear cells and inducible cell-free HIV-1 RNA in CD4+ T-cells by a prostratin analogue stimulation assay. HIV serology was quantified by signal-to-cutoff ratio (S/CO). RESULTS Of 228 enrolled participants, 69 achieved SVS for ≥5 years. HIV-1 DNA, inducible cell-free HIV-1 RNA, and S/COs correlated directly with the age of effective combination antiretroviral therapy (cART) initiation (P < .001, P = .036, and P < .001, respectively) and age when SVS was achieved (P = .002, P = .038, and P < .001, respectively) and inversely with the proportion of life spent on effective cART (P < .001, P = .01, and P < .001, respectively) and proportion of life spent with SVS (P < .001, P = .079, and P < .001, respectively). Inducible cell-free HIV-1 RNA correlated with HIV-1 DNA, most particularly in children with SVS, without virologic blips, that was achieved with the first cART regimen initiated prior to 6 months of age (rho = 0.74; P = .037) or later (rho = 0.87; P < .001). S/COs correlated with HIV-1 DNA (P = .003), but less so with inducible cell-free HIV-1 RNA (P = .09). CONCLUSIONS The prostratin analogue stimulation assay, with its lower blood volume requirement, could be a valuable method for evaluating inducible HIV-1 reservoirs in children. Standard commercial HIV serology may be a practical initial indirect measure of reservoir size in the peripheral blood of children with perinatally acquired HIV-1 infection.
Collapse
Affiliation(s)
- Ari Bitnun
- Department of Pediatrics, Hospital for Sick Children, University of Toronto, Ontario
| | - Doris G Ransy
- Centre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Quebec
| | - Jason Brophy
- Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ontario
| | - Fatima Kakkar
- Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Quebec
| | - Michael Hawkes
- Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton
| | - Lindy Samson
- Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ontario
| | - Bayader Annabi
- Centre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Quebec.,Department of Microbiology, Infectiology & Immunology, Université de Montréal, Quebec
| | - Amélie Pagliuzza
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Quebec
| | - Jacob-Adams Morand
- Centre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Quebec.,Department of Microbiology, Infectiology & Immunology, Université de Montréal, Quebec
| | - Laura Sauve
- Oak Tree Clinic, Women's Hospital and Health Centre of British Columbia, Department of Pediatrics, University of British Columbia, Vancouver
| | - Nicolas Chomont
- Department of Microbiology, Infectiology & Immunology, Université de Montréal, Quebec.,Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Quebec
| | - Stephanie Lavoie
- National Human Immunodeficiency Virus (HIV) & Retrovirology Laboratories, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - John Kim
- National Human Immunodeficiency Virus (HIV) & Retrovirology Laboratories, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Paul Sandstrom
- National Human Immunodeficiency Virus (HIV) & Retrovirology Laboratories, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Paul A Wender
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, California
| | - Terry Lee
- Canadian Institutes of Health Research Canadian HIV Trials Network, Vancouver, British Columbia
| | - Joel Singer
- Canadian Institutes of Health Research Canadian HIV Trials Network, Vancouver, British Columbia.,School of Population and Public Health, University of British Columbia, Vancouver, Canada
| | - Stanley E Read
- Department of Pediatrics, Hospital for Sick Children, University of Toronto, Ontario
| | - Hugo Soudeyns
- Centre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Quebec.,Department of Microbiology, Infectiology & Immunology, Université de Montréal, Quebec
| | | |
Collapse
|
19
|
Marsden MD, Zhang TH, Du Y, Dimapasoc M, Soliman MS, Wu X, Kim JT, Shimizu A, Schrier A, Wender PA, Sun R, Zack JA. Tracking HIV Rebound following Latency Reversal Using Barcoded HIV. Cell Rep Med 2020; 1:100162. [PMID: 33377133 PMCID: PMC7762775 DOI: 10.1016/j.xcrm.2020.100162] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 08/31/2020] [Accepted: 11/23/2020] [Indexed: 11/26/2022]
Abstract
HIV latency prevents cure of infection with antiretroviral therapy (ART) alone. One strategy for eliminating latently infected cells involves the induction of viral protein expression via latency-reversing agents (LRAs), allowing killing of host cells by viral cytopathic effects or immune effector mechanisms. Here, we combine a barcoded HIV approach and a humanized mouse model to study the effects of a designed, synthetic protein kinase C modulating LRA on HIV rebound. We show that administration of this compound during ART results in a delay in rebound once ART is stopped. Furthermore, the rebounding virus appears composed of a smaller number of unique barcoded viruses than occurs in control-treated animals, suggesting that some reservoir cells that would have contributed virus to the rebound process are eliminated by LRA administration. These data support the use of barcoded virus to study rebound and suggest that LRAs may be useful in HIV cure efforts.
Collapse
Affiliation(s)
- Matthew D. Marsden
- Department of Microbiology and Molecular Genetics and Department of Medicine, Division of Infectious Diseases, School of Medicine, University of California, Irvine, Irvine, CA 92697, USA
| | - Tian-hao Zhang
- Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Yushen Du
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA
- Cancer Institute, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Medicine, Zhejiang University, Hangzhou 310058, China
| | - Melanie Dimapasoc
- Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Mohamed S.A. Soliman
- Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Xiaomeng Wu
- Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Jocelyn T. Kim
- Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Akira Shimizu
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA
| | - Adam Schrier
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA
| | - Paul A. Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA
| | - Ren Sun
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Jerome A. Zack
- Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
- Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA
| |
Collapse
|
20
|
Wender PA, Sloane JL, Luu-Nguyen QH, Ogawa Y, Shimizu AJ, Ryckbosch SM, Tyler JH, Hardman C. Function-Oriented Synthesis: Design, Synthesis, and Evaluation of Highly Simplified Bryostatin Analogues. J Org Chem 2020; 85:15116-15128. [PMID: 33200928 DOI: 10.1021/acs.joc.0c01988] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Using a function-oriented synthesis strategy, we designed, synthesized, and evaluated the simplest bryostatin 1 analogues reported to date, in which bryostatin's A- and B-rings are replaced by a glutarate linker. These analogues, one without and one with a C26-methyl group, exhibit remarkably different protein kinase C (PKC) isoform affinities. The former exhibited bryostatin-like binding to several PKC isoforms with Ki's < 5 nM, while the latter exhibited PKC affinities that were up to ∼180-fold less potent. The analogue with bryostatin-like PKC affinities also exhibited bryostatin-like PKC translocation kinetics in vitro, indicating rapid cell permeation and engagement of its PKC target. This study exemplifies the power of function-oriented synthesis in reducing structural complexity by activity-informed design, thus enhancing synthetic accessibility, while still maintaining function (biological activity), collectively providing new leads for addressing the growing list of therapeutic indications exhibited by PKC modulators.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States.,Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Jack L Sloane
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Quang H Luu-Nguyen
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Yasuyuki Ogawa
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Akira J Shimizu
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Steven M Ryckbosch
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jefferson H Tyler
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Clayton Hardman
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
21
|
Ly C, Shimizu AJ, Vargas MV, Duim WC, Wender PA, Olson DE. Bryostatin 1 Promotes Synaptogenesis and Reduces Dendritic Spine Density in Cortical Cultures through a PKC-Dependent Mechanism. ACS Chem Neurosci 2020; 11:1545-1554. [PMID: 32437156 PMCID: PMC7332236 DOI: 10.1021/acschemneuro.0c00175] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The marine natural product bryostatin 1 has demonstrated procognitive and antidepressant effects in animals and has been entered into human clinical trials for treating Alzheimer's disease (AD). The ability of bryostatin 1 to enhance learning and memory has largely been attributed to its effects on the structure and function of hippocampal neurons. However, relatively little is known about how bryostatin 1 influences the morphology of cortical neurons, key cells that also support learning and memory processes and are negatively impacted in AD. Here, we use a combination of carefully designed chemical probes and pharmacological inhibitors to establish that bryostatin 1 increases cortical synaptogenesis while decreasing dendritic spine density in a protein kinase C (PKC)-dependent manner. The effects of bryostatin 1 on cortical neurons are distinct from those induced by neural plasticity-promoting psychoplastogens such as ketamine. Compounds capable of increasing synaptic density with concomitant loss of immature dendritic spines may represent a unique pharmacological strategy for enhancing memory by improving signal-to-noise ratio in the central nervous system.
Collapse
Affiliation(s)
- Calvin Ly
- Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, United States
| | - Akira J Shimizu
- Department of Chemistry, Stanford University, 333 Campus Drive, Stanford, California 94305, United States
| | - Maxemiliano V Vargas
- Neuroscience Graduate Program, University of California, Davis, 1544 Newton Ct, Davis, California 95618, United States
| | - Whitney C Duim
- Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, United States
| | - Paul A Wender
- Department of Chemistry, Stanford University, 333 Campus Drive, Stanford, California 94305, United States.,Chemical and Systems Biology, Stanford University, 269 Campus Drive, Stanford, California 94305, United States
| | - David E Olson
- Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, United States.,Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, California 95817, United States.,Center for Neuroscience, University of California, Davis, 1544 Newton Ct, Davis, California 95618, United States
| |
Collapse
|
22
|
Blake TR, Ho WC, Turlington CR, Zang X, Huttner MA, Wender PA, Waymouth RM. Synthesis and mechanistic investigations of pH-responsive cationic poly(aminoester)s. Chem Sci 2020; 11:2951-2966. [PMID: 34122796 PMCID: PMC8157522 DOI: 10.1039/c9sc05267d] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 02/04/2020] [Indexed: 01/24/2023] Open
Abstract
The synthesis and degradation mechanisms of a class of pH-sensitive, rapidly degrading cationic poly(α-aminoester)s are described. These reactive, cationic polymers are stable at low pH in water, but undergo a fast and selective degradation at higher pH to liberate neutral diketopiperazines. Related materials incorporating oligo(α-amino ester)s have been shown to be effective gene delivery agents, as the charge-altering degradative behavior facilitates the delivery and release of mRNA and other nucleic acids in vitro and in vivo. Herein, we report detailed studies of the structural and environmental factors that lead to these rapid and selective degradation processes in aqueous buffers. At neutral pH, poly(α-aminoester)s derived from N-hydroxyethylglycine degrade selectively by a mechanism involving sequential 1,5- and 1,6-O→N acyl shifts to generate bis(N-hydroxyethyl) diketopiperazine. A family of structurally related cationic poly(aminoester)s was generated to study the structural influences on the degradation mechanism, product distribution, and pH dependence of the rate of degradation. The kinetics and mechanism of the pH-induced degradations were investigated by 1H NMR, model reactions, and kinetic simulations. These results indicate that polyesters bearing α-ammonium groups and appropriately positioned N-hydroxyethyl substituents are readily cleaved (by intramolecular attack) or hydrolyzed, representing dynamic "dual function" materials that are initially polycationic and transform with changing environment to neutral products.
Collapse
Affiliation(s)
- Timothy R Blake
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | - Wilson C Ho
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | | | - Xiaoyu Zang
- Department of Chemistry, Stanford University Stanford CA 94305 USA
| | | | - Paul A Wender
- Department of Chemistry, Stanford University Stanford CA 94305 USA
- Department of Chemical and Systems Biology, Stanford University Stanford CA 94305 USA
| | | |
Collapse
|
23
|
Habibian M, McKinlay C, Blake TR, Kietrys AM, Waymouth RM, Wender PA, Kool ET. Reversible RNA acylation for control of CRISPR-Cas9 gene editing. Chem Sci 2019; 11:1011-1016. [PMID: 34084356 PMCID: PMC8145180 DOI: 10.1039/c9sc03639c] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
We report the development of post-transcriptional chemical methods that enable control over CRISPR–Cas9 gene editing activity both in in vitro assays and in living cells. We show that an azide-substituted acyl imidazole reagent (NAI-N3) efficiently acylates CRISPR single guide RNAs (sgRNAs) in 20 minutes in buffer. Poly-acylated (“cloaked”) sgRNA was completely inactive in DNA cleavage with Cas9 in vitro, and activity was quantitatively restored after phosphine treatment. Delivery of cloaked sgRNA and Cas9 mRNA into HeLa cells was enabled by the use of charge-altering releasable transporters (CARTs), which outperformed commercial transfection reagents in transfecting sgRNA co-complexed with Cas9 encoding functional mRNA. Genomic DNA cleavage in the cells by CRISPR–Cas9 was efficiently restored after treatment with phosphine to remove the blocking acyl groups. Our results highlight the utility of reversible RNA acylation as a novel method for temporal control of genome-editing function. We report the development of post-transcriptional chemical methods that enable control over CRISPR–Cas9 gene editing activity both in in vitro assays and in living cells.![]()
Collapse
Affiliation(s)
- Maryam Habibian
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| | - Colin McKinlay
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| | - Timothy R Blake
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| | - Anna M Kietrys
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| | - Robert M Waymouth
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| | - Paul A Wender
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| | - Eric T Kool
- Department of Chemistry, Stanford University 450 Serra Mall Stanford CA 94305 USA
| |
Collapse
|
24
|
Singh J, Ripp A, Haas TM, Qiu D, Keller M, Wender PA, Siegel JS, Baldridge KK, Jessen HJ. Correction to “Synthesis of Modified Nucleoside Oligophosphates Simplified: Fast, Pure, and Protecting Group Free”. J Am Chem Soc 2019; 141:16513. [DOI: 10.1021/jacs.9b10441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Antonoplis A, Zang X, Wegner T, Wender PA, Cegelski L. Vancomycin-Arginine Conjugate Inhibits Growth of Carbapenem-Resistant E. coli and Targets Cell-Wall Synthesis. ACS Chem Biol 2019; 14:2065-2070. [PMID: 31479234 DOI: 10.1021/acschembio.9b00565] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The emergence of multi-drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae, is a major health problem that necessitates the development of new antibiotics. Vancomycin inhibits cell-wall synthesis in Gram-positive bacteria but is generally ineffective against Gram-negative bacteria and is unable to penetrate the outer membrane barrier. In an effort to determine whether vancomycin and other antibiotics effective against Gram-positive bacteria could, through modification, be rendered effective against Gram-negative bacteria, we discovered that the covalent attachment of a single arginine to vancomycin yielded conjugates with order-of-magnitude improvements in activity against Gram-negative bacteria, including pathogenic E. coli. The vancomycin-arginine conjugate (V-R) exhibited efficacy against actively growing bacteria, induced the loss of rod cellular morphology, and resulted in the intracellular accumulation of peptidoglycan precursors, all consistent with cell-wall synthesis disruption as its mechanism of action. Membrane permeabilization studies demonstrated an enhanced outer membrane permeability of V-R as compared with vancomycin. The conjugate exhibited no mammalian cell toxicity or hemolytic activity in MTT and hemolysis assays. Our study introduces a new vancomycin derivative effective against Gram-negative bacteria and underscores the broader potential of generating new antibiotics through combined mode-of-action and synthesis-informed design studies.
Collapse
Affiliation(s)
- Alexandra Antonoplis
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Xiaoyu Zang
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Tristan Wegner
- Organisch-Chemisches Institut, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Lynette Cegelski
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
26
|
Singh J, Ripp A, Haas TM, Qiu D, Keller M, Wender PA, Siegel JS, Baldridge KK, Jessen HJ. Synthesis of Modified Nucleoside Oligophosphates Simplified: Fast, Pure, and Protecting Group Free. J Am Chem Soc 2019; 141:15013-15017. [PMID: 31512870 PMCID: PMC10044464 DOI: 10.1021/jacs.9b08273] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Phosphoramidite analogues of modified cyclotriphosphates provide a general and step-economical synthesis of nucleoside triphosphates and analogues on scale without the need for protecting groups. These reagents enable rapid access to pure nucleoside oligophosphates and a range of other analogues that were previously difficult to obtain (e.g., NH, CH2, CCl2, and CF2 replacements for O, phosphono- and phosphoimidazolides, -morpholidates, -azidates, and -fluoridates). DFT calculations demonstrate that the selectivity of the cyclotriphosphate opening reactions proceeds via an in-line substitution mechanism that displaces the least charged leaving group.
Collapse
Affiliation(s)
- Jyoti Singh
- Institute of Organic Chemistry, University of Freiburg, D-79104 Freiburg, Germany
| | - Alexander Ripp
- Institute of Organic Chemistry, University of Freiburg, D-79104 Freiburg, Germany
- Cluster of Excellence livMatS @ FIT − Freiburg Center for Interactive Materials and Bioinspired Technologies, University of Freiburg, Georges-Köhler-Allee 105, D-79110 Freiburg, Germany
| | - Thomas M. Haas
- Institute of Organic Chemistry, University of Freiburg, D-79104 Freiburg, Germany
| | - Danye Qiu
- Institute of Organic Chemistry, University of Freiburg, D-79104 Freiburg, Germany
| | - Manfred Keller
- Institute of Organic Chemistry, University of Freiburg, D-79104 Freiburg, Germany
| | - Paul A. Wender
- Chemistry Department, Stanford University, 333 Campus Drive, Stanford, California 94305-5080, United States
| | - Jay S. Siegel
- Health Science Platform, Tianjin University, Nankai District, Tianjin, PRC 30072
- Freiburg Research Institute for Advanced Studies, University of Freiburg, D-79104 Freiburg, Germany
| | - Kim K. Baldridge
- Health Science Platform, Tianjin University, Nankai District, Tianjin, PRC 30072
| | - Henning J. Jessen
- Institute of Organic Chemistry, University of Freiburg, D-79104 Freiburg, Germany
- Freiburg Research Institute for Advanced Studies, University of Freiburg, D-79104 Freiburg, Germany
- Cluster of Excellence livMatS @ FIT − Freiburg Center for Interactive Materials and Bioinspired Technologies, University of Freiburg, Georges-Köhler-Allee 105, D-79110 Freiburg, Germany
| |
Collapse
|
27
|
Huiting ED, Gittens K, Justement JS, Shi V, Blazkova J, Benko E, Kovacs C, Wender PA, Moir S, Sneller MC, Fauci AS, Chun TW. Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection. J Infect Dis 2019; 220:270-274. [PMID: 30840763 PMCID: PMC6941494 DOI: 10.1093/infdis/jiz100] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 03/05/2019] [Indexed: 12/26/2022] Open
Abstract
Therapeutic strategies for achieving sustained virologic remission are being explored in human immunodeficiency virus (HIV)-infected individuals who began antiretroviral therapy (ART) during the early phase of infection. In the evaluation of such therapies, clinical protocols should include analytical treatment interruption (ATI); however, the immunologic and virologic impact of ATI in individuals who initiated ART early has not been fully delineated. We demonstrate that ATI causes neither expansion of HIV reservoirs nor immunologic abnormalities following reinitiation of ART. Our findings support the use of ATI to determine whether sustained virologic remission has been achieved in clinical trials of individuals who initiated ART early during HIV infection.
Collapse
Affiliation(s)
- Erin D Huiting
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | - Kathleen Gittens
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland
| | - J Shawn Justement
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | - Victoria Shi
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | - Jana Blazkova
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | | | | | | | - Susan Moir
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | - Michael C Sneller
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | - Anthony S Fauci
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| | - Tae-Wook Chun
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
| |
Collapse
|
28
|
Benner NL, McClellan RL, Turlington CR, Haabeth OAW, Waymouth RM, Wender PA. Oligo(serine ester) Charge-Altering Releasable Transporters: Organocatalytic Ring-Opening Polymerization and their Use for in Vitro and in Vivo mRNA Delivery. J Am Chem Soc 2019; 141:8416-8421. [PMID: 31083999 PMCID: PMC7209379 DOI: 10.1021/jacs.9b03154] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
RNA technology is transforming life science research and medicine, but many applications are limited by the accessibility, cost, efficacy, and tolerability of delivery systems. Here we report the first members of a new class of dynamic RNA delivery vectors, oligo(serine ester)-based charge-altering releasable transporters (Ser-CARTs). Composed of lipid-containing oligocarbonates and cationic oligo(serine esters), Ser-CARTs are readily prepared (one flask) by a mild ring-opening polymerization using thiourea anions and, upon simple mixing with mRNA, readily form complexes that degrade to neutral serine-based products, efficiently releasing their mRNA cargo. mRNA/Ser-CART transfection efficiencies of >95% are achieved in vitro. Intramuscular or intravenous (iv) injections of mRNA/Ser-CARTs into living mice result in in vivo expression of a luciferase reporter protein, with spleen localization observed after iv injection.
Collapse
Affiliation(s)
- Nancy L. Benner
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Rebecca L. McClellan
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | | | - Ole A. W. Haabeth
- Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States
| | - Robert M. Waymouth
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
29
|
Singh J, Steck N, De D, Hofer A, Ripp A, Captain I, Keller M, Wender PA, Bhandari R, Jessen HJ. A Phosphoramidite Analogue of Cyclotriphosphate Enables Iterative Polyphosphorylations. Angew Chem Int Ed Engl 2019; 58:3928-3933. [DOI: 10.1002/anie.201814366] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Indexed: 12/20/2022]
Affiliation(s)
- Jyoti Singh
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Nicole Steck
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Debaditya De
- Laboratory of Cell Signaling, CDFD Hyderabad India
| | - Alexandre Hofer
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Alexander Ripp
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Ilya Captain
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Manfred Keller
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Paul A. Wender
- Stanford UniversityChemistry Department 333 Campus Drive Stanford CA 94305-5080 USA
| | | | - Henning J. Jessen
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| |
Collapse
|
30
|
Singh J, Steck N, De D, Hofer A, Ripp A, Captain I, Keller M, Wender PA, Bhandari R, Jessen HJ. A Phosphoramidite Analogue of Cyclotriphosphate Enables Iterative Polyphosphorylations. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201814366] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Jyoti Singh
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Nicole Steck
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Debaditya De
- Laboratory of Cell Signaling, CDFD Hyderabad India
| | - Alexandre Hofer
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Alexander Ripp
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Ilya Captain
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Manfred Keller
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| | - Paul A. Wender
- Stanford UniversityChemistry Department 333 Campus Drive Stanford CA 94305-5080 USA
| | | | - Henning J. Jessen
- University of FreiburgInstitute of Organic Chemistry Albertstrasse 21 79104 Freiburg Germany
| |
Collapse
|
31
|
Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, Wender PA, Levy R. Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity. Cancer Res 2019; 79:1624-1634. [PMID: 30692215 DOI: 10.1158/0008-5472.can-18-2867] [Citation(s) in RCA: 71] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 12/04/2018] [Accepted: 01/23/2019] [Indexed: 12/19/2022]
Abstract
Localized expression of effector molecules can initiate antitumor responses through engagement of specific receptors on target cells in the tumor microenvironment. These locally induced responses may also have a systemic effect, clearing additional tumors throughout the body. In this study, to evoke systemic antitumor responses, we utilized charge-altering releasable transporters (CART) for local intratumoral delivery of mRNA coding for costimulatory and immune-modulating factors. Intratumoral injection of the CART-mRNA complexes resulted in mRNA expression at the site of administration, transfecting a substantial proportion of tumor-infiltrating dendritic cells, macrophages, and T cells in addition to the tumor cells, resulting in a local antitumor effect. Using a two-tumor model, we further show that mRNA therapy locally administered to one tumor stimulated a systemic antitumor response, curing both tumors. The combination of Ox40l-, Cd80-, and Cd86-encoding mRNA resulted in the local upregulation of proinflammatory cytokines, robust local T-cell activation, and migration of immune cells to local draining lymph node or to an anatomically distant tumor. This approach delayed tumor growth, facilitated tumor regression, and cured tumors in both A20 and CT26 tumor models. These results highlight mRNA-CART therapy as a viable approach to induce systemic antitumor immunity from a single localized injection. SIGNIFICANCE: The mRNA-CART system is a highly effective delivery platform for delivering immunostimulatory genes into the tumor microenvironment for potential therapeutic development.
Collapse
Affiliation(s)
- Ole Audun Werner Haabeth
- Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, California.,Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.,KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway
| | - Timothy R Blake
- Department of Chemistry, Stanford University, Stanford, California
| | - Colin J McKinlay
- Department of Chemistry, Stanford University, Stanford, California
| | - Anders A Tveita
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.,KG Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway
| | - Adrienne Sallets
- Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, California
| | | | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California.,Department of Chemical and Systems Biology, Stanford University, Stanford, California
| | - Ronald Levy
- Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, California.
| |
Collapse
|
32
|
Antonoplis A, Zang X, Huttner MA, Chong KKL, Lee YB, Co JY, Amieva MR, Kline KA, Wender PA, Cegelski L. A Dual-Function Antibiotic-Transporter Conjugate Exhibits Superior Activity in Sterilizing MRSA Biofilms and Killing Persister Cells. J Am Chem Soc 2018; 140:16140-16151. [PMID: 30388366 PMCID: PMC6430714 DOI: 10.1021/jacs.8b08711] [Citation(s) in RCA: 93] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
New strategies are urgently needed to target MRSA, a major global health problem and the leading cause of mortality from antibiotic-resistant infections in many countries. Here, we report a general approach to this problem exemplified by the design and synthesis of a vancomycin-d-octaarginine conjugate (V-r8) and investigation of its efficacy in addressing antibiotic-insensitive bacterial populations. V-r8 eradicated MRSA biofilm and persister cells in vitro, outperforming vancomycin by orders of magnitude. It also eliminated 97% of biofilm-associated MRSA in a murine wound infection model and displayed no acute dermal toxicity. This new dual-function conjugate displays enhanced cellular accumulation and membrane perturbation as compared to vancomycin. Based on its rapid and potent activity against biofilm and persister cells, V-r8 is a promising agent against clinical MRSA infections.
Collapse
Affiliation(s)
- Alexandra Antonoplis
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Xiaoyu Zang
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Melanie A. Huttner
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Kelvin K. L. Chong
- Singapore Centre for Environmental Life Science Engineering (SCELSE), School of Biological Sciences, Nanyang Technological University, Singapore 637551
- Nanyang Technological University Institute for Health Technologies, Interdisciplinary Graduate School, Nanyang Technological University, Singapore 637553
| | - Yu B. Lee
- Singapore Centre for Environmental Life Science Engineering (SCELSE), School of Biological Sciences, Nanyang Technological University, Singapore 637551
| | - Julia Y. Co
- Department of Pediatrics, Division of Infectious Diseases, Stanford University, Stanford, California 94305, United States
| | - Manuel R. Amieva
- Department of Pediatrics, Division of Infectious Diseases, Stanford University, Stanford, California 94305, United States
- Department of Microbiology & Immunology, Stanford University, Stanford, California 94305, United States
| | - Kimberly A. Kline
- Singapore Centre for Environmental Life Science Engineering (SCELSE), School of Biological Sciences, Nanyang Technological University, Singapore 637551
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Lynette Cegelski
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
33
|
Fernandes-Cunha G, McKinlay CJ, Vargas JR, Jessen HJ, Waymouth RM, Wender PA. Delivery of Inorganic Polyphosphate into Cells Using Amphipathic Oligocarbonate Transporters. ACS Cent Sci 2018; 4:1394-1402. [PMID: 30410977 PMCID: PMC6202642 DOI: 10.1021/acscentsci.8b00470] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Indexed: 05/10/2023]
Abstract
Inorganic polyphosphate (polyP) is an often-overlooked biopolymer of phosphate residues present in living cells. PolyP is associated with many essential biological roles. Despite interest in polyP's function, most studies have been limited to extracellular or isolated protein experiments, as polyanionic polyP does not traverse the nonpolar membrane of cells. To address this problem, we developed a robust, readily employed method for polyP delivery using guanidinium-rich oligocarbonate transporters that electrostatically complex polyPs of multiple lengths, forming discrete nanoparticles that are resistant to phosphatase degradation and that readily enter multiple cell types. Fluorescently labeled polyPs have been monitored over time for subcellular localization and release from the transporter, with control over release rates achieved by modulating the transporter identity and the charge ratio of the electrostatic complexes. This general approach to polyP delivery enables the study of intracellular polyP signaling in a variety of applications.
Collapse
Affiliation(s)
- Gabriella
M. Fernandes-Cunha
- Department
of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Colin J. McKinlay
- Department
of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Jessica R. Vargas
- Department
of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Henning J. Jessen
- Institute
of Organic Chemistry, Albert-Ludwigs University, Freiburg Albertstr. 21, 79104 Freiburg, Germany
| | - Robert M. Waymouth
- Department
of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Paul A. Wender
- Department
of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
34
|
Benner NL, Near KE, Bachmann MH, Contag CH, Waymouth RM, Wender PA. Functional DNA Delivery Enabled by Lipid-Modified Charge-Altering Releasable Transporters (CARTs). Biomacromolecules 2018; 19:2812-2824. [PMID: 29727572 PMCID: PMC6542359 DOI: 10.1021/acs.biomac.8b00401] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Safe and effective DNA delivery systems are required to enable or enhance clinical strategies and research involving gene therapy and DNA vaccinations. To address this delivery problem, a series of charge-altering releasable transporters (CARTs) with varied lipid content were prepared and evaluated for plasmid DNA (pDNA) delivery into cultured cells. These lipid-modified CART co-oligomers were synthesized in only two steps via sequential organocatalytic ring-opening polymerization of lipid-containing cyclic carbonate monomers and morpholinone monomers. Lipid variations of the CARTs substantially impacted the delivery efficiency of pDNA, with oleyl- and linoleyl-based CARTs showing enhanced performance relative to the commercial transfection agent Lipofectamine 2000 (L2000). The best-performing oleyl CART was carried forward to study stable luciferase transfection with a Sleeping Beauty ( SB) transposon system. The oleyl CART outperformed the L2000 positive control with respect to stable transfection efficiency. CART-pDNA complexes represent a new DNA delivery system for research and clinical applications.
Collapse
Affiliation(s)
- Nancy L. Benner
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Katherine E. Near
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Michael H. Bachmann
- Department of Pediatrics, Stanford University, Stanford, California 94305, United States
| | - Christopher H. Contag
- Department of Pediatrics, Stanford University, Stanford, California 94305, United States
- Department of Microbiology and Immunology, Stanford University, Stanford, California 94305, United States
- Department of Radiology, Stanford University, Stanford, California 94305, United States
| | - Robert M. Waymouth
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
35
|
Marsden MD, Wu X, Navab SM, Loy BA, Schrier AJ, DeChristopher BA, Shimizu AJ, Hardman CT, Ho S, Ramirez CM, Wender PA, Zack JA. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 2018; 520:83-93. [PMID: 29800728 PMCID: PMC6018613 DOI: 10.1016/j.virol.2018.05.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 05/09/2018] [Accepted: 05/10/2018] [Indexed: 11/15/2022]
Abstract
HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with antiretroviral drugs alone. Latency reversing agents (LRAs) can activate HIV expression in latently infected cells, potentially leading to their elimination through virus-mediated cytopathic effects, host immune responses, and/or therapeutic strategies targeting cells actively expressing virus. We have recently described several structurally simplified analogs of the PKC modulator LRA bryostatin (termed bryologs) designed to improve synthetic accessibility, tolerability in vivo, and efficacy in inducing HIV latency reversal. Here we report the comparative performance of lead bryologs, including their effects in reducing cell surface expression of HIV entry receptors, inducing proinflammatory cytokines, inhibiting short-term HIV replication, and synergizing with histone deacetylase inhibitors to reverse HIV latency. These data provide unique insights into structure-function relationships between A- and B-ring bryolog modifications and activities in primary cells, and suggest that bryologs represent promising leads for preclinical advancement.
Collapse
Affiliation(s)
- Matthew D Marsden
- Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095, United States.
| | - Xiaomeng Wu
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA 90095, United States
| | - Sara M Navab
- Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095, United States
| | - Brian A Loy
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States
| | - Adam J Schrier
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States
| | - Brian A DeChristopher
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States
| | - Akira J Shimizu
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States
| | - Clayton T Hardman
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States
| | - Stephen Ho
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States
| | - Christina M Ramirez
- Department of Biostatistics, School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, United States
| | - Paul A Wender
- Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, United States.
| | - Jerome A Zack
- Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095, United States; Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA 90095, United States
| |
Collapse
|
36
|
Yang H, Staveness D, Ryckbosch SM, Axtman AD, Loy BA, Barnes AB, Pande VS, Schaefer J, Wender PA, Cegelski L. REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment. ACS Cent Sci 2018; 4:89-96. [PMID: 29392180 PMCID: PMC5785774 DOI: 10.1021/acscentsci.7b00475] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Indexed: 05/05/2023]
Abstract
Bryostatin 1 (henceforth bryostatin) is in clinical trials for the treatment of Alzheimer's disease and for HIV/AIDS eradication. It is also a preclinical lead for cancer immunotherapy and other therapeutic indications. Yet nothing is known about the conformation of bryostatin bound to its protein kinase C (PKC) target in a membrane microenvironment. As a result, efforts to design more efficacious, better tolerated, or more synthetically accessible ligands have been limited to structures that do not include PKC or membrane effects known to influence PKC-ligand binding. This problem extends more generally to many membrane-associated proteins in the human proteome. Here, we use rotational-echo double-resonance (REDOR) solid-state NMR to determine the conformations of PKC modulators bound to the PKCδ-C1b domain in the presence of phospholipid vesicles. The conformationally limited PKC modulator phorbol diacetate (PDAc) is used as an initial test substrate. While unanticipated partitioning of PDAc between an immobilized protein-bound state and a mobile state in the phospholipid assembly was observed, a single conformation in the bound state was identified. In striking contrast, a bryostatin analogue (bryolog) was found to exist exclusively in a protein-bound state, but adopts a distribution of conformations as defined by three independent distance measurements. The detection of multiple PKCδ-C1b-bound bryolog conformers in a functionally relevant phospholipid complex reveals the inherent dynamic nature of cellular systems that is not captured with single-conformation static structures. These results indicate that binding, selectivity, and function of PKC modulators, as well as the design of new modulators, are best addressed using a dynamic multistate model, an analysis potentially applicable to other membrane-associated proteins.
Collapse
Affiliation(s)
- Hao Yang
- Department
of Chemistry, Washington University in St.
Louis, St. Louis, Missouri 63130, United
States
| | - Daryl Staveness
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Steven M. Ryckbosch
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Alison D. Axtman
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Brian A. Loy
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Alexander B. Barnes
- Department
of Chemistry, Washington University in St.
Louis, St. Louis, Missouri 63130, United
States
| | - Vijay S. Pande
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jacob Schaefer
- Department
of Chemistry, Washington University in St.
Louis, St. Louis, Missouri 63130, United
States
| | - Paul A. Wender
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
- Department
of Chemical and Systems Biology, Stanford
University, Stanford, California 94305, United States
| | - Lynette Cegelski
- Department
of Chemistry, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
37
|
Wender PA, Hardman CT, Ho S, Jeffreys MS, Maclaren JK, Quiroz RV, Ryckbosch SM, Shimizu AJ, Sloane JL, Stevens MC. Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 2018; 358:218-223. [PMID: 29026042 DOI: 10.1126/science.aan7969] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Accepted: 08/04/2017] [Indexed: 11/02/2022]
Abstract
Bryostatin 1 is an exceedingly scarce marine-derived natural product that is in clinical development directed at HIV/AIDS eradication, cancer immunotherapy, and the treatment of Alzheimer's disease. Despite this unique portfolio of indications, its availability has been limited and variable, thus impeding research and clinical studies. Here, we report a total synthesis of bryostatin 1 that proceeds in 29 total steps (19 in the longest linear sequence, >80% average yield per step), collectively produces grams of material, and can be scaled to meet clinical needs (~20 grams per year). This practical solution to the bryostatin supply problem also opens broad, facile, and efficient access to derivatives and potentially superior analogs.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA. .,Department of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA
| | - Clayton T Hardman
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | - Stephen Ho
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | | | - Jana K Maclaren
- Stanford Nano Shared Facilities, Stanford University, Stanford, CA 94305, USA
| | - Ryan V Quiroz
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | | | - Akira J Shimizu
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | - Jack L Sloane
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | - Matthew C Stevens
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| |
Collapse
|
38
|
Affiliation(s)
- Paul A Wender
- Paul A. Wender is a professor of chemistry at Stanford University, California, USA. In 1974, he was a US National Institutes of Health postdoctoral fellow working with Stork, in part on quinine and then on reserpine
| |
Collapse
|
39
|
Wender PA, Ebner C, Fennell BD, Inagaki F, Schröder B. Ynol Ethers as Ketene Equivalents in Rhodium-Catalyzed Intermolecular [5 + 2] Cycloaddition Reactions. Org Lett 2017; 19:5810-5813. [PMID: 29034684 PMCID: PMC5833981 DOI: 10.1021/acs.orglett.7b02765] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The previously unexplored metal-catalyzed [5 + 2] cycloadditions of vinylcyclopropanes (VCPs) and electron-rich alkynes (ynol ethers) have been found to provide a highly efficient, direct route to dioxygenated seven-membered rings, a common feature of numerous natural and non-natural targets and building blocks for synthesis. The reactions proceed in high yield at room temperature and tolerate a broad range of functionalities. Substituted VCPs were found to react with high regioselectivity.
Collapse
Affiliation(s)
- Paul A. Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Christian Ebner
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Brandon D. Fennell
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | | | | |
Collapse
|
40
|
Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, Shimizu A, Ryckbosch SM, Near KE, Chun TW, Wender PA, Zack JA. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. PLoS Pathog 2017; 13:e1006575. [PMID: 28934369 PMCID: PMC5608406 DOI: 10.1371/journal.ppat.1006575] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Accepted: 08/10/2017] [Indexed: 12/27/2022] Open
Abstract
The ability of HIV to establish a long-lived latent infection within resting CD4+ T cells leads to persistence and episodic resupply of the virus in patients treated with antiretroviral therapy (ART), thereby preventing eradication of the disease. Protein kinase C (PKC) modulators such as bryostatin 1 can activate these latently infected cells, potentially leading to their elimination by virus-mediated cytopathic effects, the host's immune response and/or therapeutic strategies targeting cells actively expressing virus. While research in this area has focused heavily on naturally-occurring PKC modulators, their study has been hampered by their limited and variable availability, and equally significantly by sub-optimal activity and in vivo tolerability. Here we show that a designed, synthetically-accessible analog of bryostatin 1 is better-tolerated in vivo when compared with the naturally-occurring product and potently induces HIV expression from latency in humanized BLT mice, a proven and important model for studying HIV persistence and pathogenesis in vivo. Importantly, this induction of virus expression causes some of the newly HIV-expressing cells to die. Thus, designed, synthetically-accessible, tunable, and efficacious bryostatin analogs can mediate both a "kick" and "kill" response in latently-infected cells and exhibit improved tolerability, therefore showing unique promise as clinical adjuvants for HIV eradication.
Collapse
Affiliation(s)
- Matthew D. Marsden
- Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, California, United States of America
| | - Brian A. Loy
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
| | - Xiaomeng Wu
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America
| | - Christina M. Ramirez
- Department of Biostatistics, School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America
| | - Adam J. Schrier
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
| | - Danielle Murray
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Akira Shimizu
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
| | - Steven M. Ryckbosch
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
| | - Katherine E. Near
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
| | - Tae-Wook Chun
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Paul A. Wender
- Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
- * E-mail: (JAZ); (PAW)
| | - Jerome A. Zack
- Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, California, United States of America
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America
- * E-mail: (JAZ); (PAW)
| |
Collapse
|
41
|
Khan TK, Wender PA, Alkon DL. Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents. J Cell Physiol 2017; 233:1523-1534. [PMID: 28590053 DOI: 10.1002/jcp.26043] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 06/06/2017] [Indexed: 11/09/2022]
Abstract
Skin health is associated with the day-to-day activity of fibroblasts. The primary function of fibroblasts is to synthesize structural proteins, such as collagen, extracellular matrix proteins, and other proteins that support the structural integrity of the skin and are associated with younger, firmer, and more elastic skin that is better able to resist and recover from injury. At sub-nanomolar concentrations (0.03-0.3 nM), bryostatin-1 and its synthetic analog, picolog (0.1-10 nM) sustained the survival and activation of human dermal fibroblasts cultured under the stressful condition of prolonged serum deprivation. Bryostatin-1 treatment stabilized human skin equivalents (HSEs), a bioengineered combination of primary human skin cells (keratinocytes and dermal fibroblasts) on an extracellular matrix composed of mainly collagen. Fibroblasts activated by bryostatin-1 protected the structural integrity of HSEs. Bryostatin-1 and picolog prolonged activation of Erk in fibroblasts to promote cell survival. Chronic stress promotes the progression of apoptosis. Dermal fibroblasts constitutively express all components of Fas associated apoptosis, including caspase-8, an initiator enzyme of apoptosis. Prolong bryostatin-1 treatment reduced apoptosis by decreasing caspase-8 and protected dermal fibroblasts. Our data suggest that bryostatin-1 and picolog could be useful in anti-aging skincare, and could have applications in tissue engineering and regenerative medicine.
Collapse
Affiliation(s)
- Tapan K Khan
- Center for Neurodegenerative Diseases, Blanchette Rockefeller Neurosciences Institute at West Virginia University, Morgantown, West Virginia
| | - Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California.,Department of Chemical and Systems Biology, Stanford University, Stanford, California
| | | |
Collapse
|
42
|
Benner NL, Zang X, Buehler DC, Kickhoefer VA, Rome ME, Rome LH, Wender PA. Vault Nanoparticles: Chemical Modifications for Imaging and Enhanced Delivery. ACS Nano 2017; 11:872-881. [PMID: 28029784 PMCID: PMC5372831 DOI: 10.1021/acsnano.6b07440] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Vault nanoparticles represent promising vehicles for drug and probe delivery. Innately found within human cells, vaults are stable, biocompatible nanocapsules possessing an internal volume that can encapsulate hundreds to thousands of molecules. They can also be targeted. Unlike most nanoparticles, vaults are nonimmunogenic and monodispersed and can be rapidly produced in insect cells. Efforts to create vaults with modified properties have been, to date, almost entirely limited to recombinant bioengineering approaches. Here we report a systematic chemical study of covalent vault modifications, directed at tuning vault properties for research and clinical applications, such as imaging, targeted delivery, and enhanced cellular uptake. As supra-macromolecular structures, vaults contain thousands of derivatizable amino acid side chains. This study is focused on establishing the comparative selectivity and efficiency of chemically modifying vault lysine and cysteine residues, using Michael additions, nucleophilic substitutions, and disulfide exchange reactions. We also report a strategy that converts the more abundant vault lysine residues to readily functionalizable thiol terminated side chains through treatment with 2-iminothiolane (Traut's reagent). These studies provide a method to doubly modify vaults with cell penetrating peptides and imaging agents, allowing for in vitro studies on their enhanced uptake into cells.
Collapse
Affiliation(s)
- Nancy L. Benner
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Xiaoyu Zang
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Daniel C. Buehler
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Valerie A. Kickhoefer
- Department of Biological Chemistry, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, United States
| | - Michael E. Rome
- Department of Biological Chemistry, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, United States
| | - Leonard H. Rome
- Department of Biological Chemistry, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, United States
| | - Paul A. Wender
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
- Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
43
|
Staveness D, Abdelnabi R, Near KE, Nakagawa Y, Neyts J, Delang L, Leyssen P, Wender PA. Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway. J Nat Prod 2016; 79:680-4. [PMID: 26900711 PMCID: PMC4942189 DOI: 10.1021/acs.jnatprod.5b01017] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Chikungunya virus (CHIKV) has been spreading rapidly, with over one million confirmed or suspected cases in the Americas since late 2013. Infection with CHIKV causes devastating arthritic and arthralgic symptoms. Currently, there is no therapy to treat this disease, and the only medications focus on relief of symptoms. Recently, protein kinase C (PKC) modulators have been reported to inhibit CHIKV-induced cell death in cell assays. The salicylate-derived bryostatin analogues described here are structurally simplified PKC modulators that are more synthetically accessible than the natural product bryostatin 1, a PKC modulator and clinical lead for the treatment of cancer, Alzheimer's disease, and HIV eradication. Evaluation of the anti-CHIKV activity of these salicylate-derived bryostatin analogues in cell culture indicates that they are among the most potent cell-protective agents reported to date. Given that they are more accessible and significantly more active than the parent natural product, they represent new therapeutic leads for controlling CHIKV infection. Significantly, these analogues also provide evidence for the involvement of a PKC-independent pathway. This adds a fundamentally distinct aspect to the importance or involvement of PKC modulation in inhibition of chikungunya virus replication, a topic of recent and growing interest.
Collapse
Affiliation(s)
- Daryl Staveness
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Rana Abdelnabi
- Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven–University of Leuven, B-3000 Leuven, Belgium
| | - Katherine E. Near
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Yu Nakagawa
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Johan Neyts
- Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven–University of Leuven, B-3000 Leuven, Belgium
| | - Leen Delang
- Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven–University of Leuven, B-3000 Leuven, Belgium
| | - Pieter Leyssen
- Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven–University of Leuven, B-3000 Leuven, Belgium
| | - Paul A. Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
44
|
Staveness D, Abdelnabi R, Schrier AJ, Loy B, Verma VA, DeChristopher BA, Near KE, Neyts J, Delang L, Leyssen P, Wender PA. Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death. J Nat Prod 2016; 79:675-9. [PMID: 26900625 PMCID: PMC4928627 DOI: 10.1021/acs.jnatprod.5b01016] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Indexed: 05/21/2023]
Abstract
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus showing a recent resurgence and rapid spread worldwide. While vaccines are under development, there are currently no therapies to treat this disease, except for over-the-counter (OTC) analgesics, which alleviate the devastating arthritic and arthralgic symptoms. To identify novel inhibitors of the virus, analogues of the natural product bryostatin 1, a clinical lead for the treatment of cancer, Alzheimer's disease, and HIV eradication, were investigated for in vitro antiviral activity and were found to be among the most potent inhibitors of CHIKV replication reported to date. Bryostatin-based therapeutic efforts and even recent anti-CHIKV strategies have centered on modulation of protein kinase C (PKC). Intriguingly, while the C ring of bryostatin primarily drives interactions with PKC, A- and B-ring functionality in these analogues has a significant effect on the observed cell-protective activity. Significantly, bryostatin 1 itself, a potent pan-PKC modulator, is inactive in these assays. These new findings indicate that the observed anti-CHIKV activity is not solely mediated by PKC modulation, suggesting possible as yet unidentified targets for CHIKV therapeutic intervention. The high potency and low toxicity of these bryologs make them promising new leads for the development of a CHIKV treatment.
Collapse
Affiliation(s)
- Daryl Staveness
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Rana Abdelnabi
- Department of Microbiology and Immunology, Rega Institute for Medical
Research, Laboratory of Virology and Chemotherapy, KU Leuven−University of Leuven, B-3000 Leuven, Belgium
| | - Adam J. Schrier
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Brian
A. Loy
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Vishal A. Verma
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Brian A. DeChristopher
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Katherine E. Near
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Johan Neyts
- Department of Microbiology and Immunology, Rega Institute for Medical
Research, Laboratory of Virology and Chemotherapy, KU Leuven−University of Leuven, B-3000 Leuven, Belgium
- E-mail:
| | - Leen Delang
- Department of Microbiology and Immunology, Rega Institute for Medical
Research, Laboratory of Virology and Chemotherapy, KU Leuven−University of Leuven, B-3000 Leuven, Belgium
| | - Pieter Leyssen
- Department of Microbiology and Immunology, Rega Institute for Medical
Research, Laboratory of Virology and Chemotherapy, KU Leuven−University of Leuven, B-3000 Leuven, Belgium
| | - Paul A. Wender
- Departments of Chemistry and Chemical and
Systems Biology, Stanford University, Stanford, California 94305, United States
- E-mail:
| |
Collapse
|
45
|
McKinlay CJ, Waymouth RM, Wender PA. Cell-Penetrating, Guanidinium-Rich Oligophosphoesters: Effective and Versatile Molecular Transporters for Drug and Probe Delivery. J Am Chem Soc 2016; 138:3510-7. [PMID: 26900771 DOI: 10.1021/jacs.5b13452] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The design, synthesis, and biological evaluation of a new family of highly effective cell-penetrating molecular transporters, guanidinium-rich oligophosphoesters, are described. These unique transporters are synthesized in two steps, irrespective of oligomer length, by the organocatalytic ring-opening polymerization (OROP) of 5-membered cyclic phospholane monomers followed by oligomer deprotection. Varying the initiating alcohol results in a wide variety of cargo attachment strategies for releasable or nonreleasable transporter applications. Initiation of oligomerization with a fluorescent probe produces, upon deprotection, a transporter-probe conjugate that is shown to readily enter multiple cell lines in a dose-dependent manner. These new transporters are superior in cell uptake to previously studied guanidinium-rich oligocarbonates and oligoarginines, showing over 2-fold higher uptake than the former and 6-fold higher uptake than the latter. Initiation with a protected thiol gives, upon deprotection, thiol-terminated transporters which can be thiol-click conjugated to a variety of probes, drugs and other cargos as exemplified by the conjugation and delivery of the model probe fluorescein-maleimide and the medicinal agent paclitaxel (PTX) into cells. Of particular significance given that drug resistance is a major cause of chemotherapy failure, the PTX-transporter conjugate, designed to evade Pgp export and release free PTX after cell entry, shows efficacy against PTX-resistant ovarian cancer cells. Collectively this study introduces a new and highly effective class of guanidinium-rich cell-penetrating transporters and methodology for their single-step conjugation to drugs and probes, and demonstrates that the resulting drug/probe-conjugates readily enter cells, outperforming previously reported guanidinium-rich oligocarbonates and peptide transporters.
Collapse
Affiliation(s)
- Colin J McKinlay
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| | - Robert M Waymouth
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| | - Paul A Wender
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| |
Collapse
|
46
|
Pavlovic I, Thakor DT, Vargas JR, McKinlay CJ, Hauke S, Anstaett P, Camuña RC, Bigler L, Gasser G, Schultz C, Wender PA, Jessen HJ. Cellular delivery and photochemical release of a caged inositol-pyrophosphate induces PH-domain translocation in cellulo. Nat Commun 2016; 7:10622. [PMID: 26842801 PMCID: PMC4743007 DOI: 10.1038/ncomms10622] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 01/05/2016] [Indexed: 02/07/2023] Open
Abstract
Inositol pyrophosphates, such as diphospho-myo-inositol pentakisphosphates (InsP7), are an important family of signalling molecules, implicated in many cellular processes and therapeutic indications including insulin secretion, glucose homeostasis and weight gain. To understand their cellular functions, chemical tools such as photocaged analogues for their real-time modulation in cells are required. Here we describe a concise, modular synthesis of InsP7 and caged InsP7. The caged molecule is stable and releases InsP7 only on irradiation. While photocaged InsP7 does not enter cells, its cellular uptake is achieved using nanoparticles formed by association with a guanidinium-rich molecular transporter. This novel synthesis and unprecedented polyphosphate delivery strategy enable the first studies required to understand InsP7 signalling in cells with controlled spatiotemporal resolution. It is shown herein that cytoplasmic photouncaging of InsP7 leads to translocation of the PH-domain of Akt, an important signalling-node kinase involved in glucose homeostasis, from the membrane into the cytoplasm. Photocaged inositol-pyrophosphates offer a tool to study cellular signalling, but their challenging synthesis has precluded any biological studies so far. Here, the authors report the synthesis and cellular delivery of a photocaged analogue, and show that it mediates protein translocation in cellulo.
Collapse
Affiliation(s)
- Igor Pavlovic
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland
| | - Divyeshsinh T Thakor
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland
| | - Jessica R Vargas
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, USA
| | - Colin J McKinlay
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, USA
| | - Sebastian Hauke
- European Molecular Biology Laboratory (EMBL), Cell Biology &Biophysics Unit, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - Philipp Anstaett
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland
| | - Rafael C Camuña
- Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Málaga, Malaga 29071, Spain
| | - Laurent Bigler
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland
| | - Gilles Gasser
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland
| | - Carsten Schultz
- European Molecular Biology Laboratory (EMBL), Cell Biology &Biophysics Unit, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - Paul A Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, USA
| | - Henning J Jessen
- Department of Chemistry and Pharmacy, Albert-Ludwigs University Freiburg, Albertstrasse 21, 79104 Freiburg, Germany
| |
Collapse
|
47
|
Hsu HT, Trantow BM, Waymouth RM, Wender PA. Bioorthogonal Catalysis: A General Method To Evaluate Metal-Catalyzed Reactions in Real Time in Living Systems Using a Cellular Luciferase Reporter System. Bioconjug Chem 2015; 27:376-82. [PMID: 26367192 PMCID: PMC4772775 DOI: 10.1021/acs.bioconjchem.5b00469] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
![]()
The development of abiological catalysts
that can function in biological
systems is an emerging subject of importance with significant ramifications
in synthetic chemistry and the life sciences. Herein we report a biocompatible
ruthenium complex [Cp(MQA)Ru(C3H5)]+PF6–2 (Cp = cyclopentadienyl,
MQA = 4-methoxyquinoline-2-carboxylate) and a general analytical method
for evaluating its performance in real time based on a luciferase
reporter system amenable to high throughput screening in cells and
by extension to evaluation in luciferase transgenic animals. Precatalyst 2 activates alloc-protected aminoluciferin 4b, a bioluminescence pro-probe, and releases the active luminophore,
aminoluciferin (4a), in the presence of luciferase-transfected
cells. The formation and enzymatic turnover of 4a, an
overall process selected because it emulates pro-drug activation and
drug turnover by an intracellular target, is evaluated in real time
by photon counting as 4a is converted by intracellular
luciferase to oxyaminoluciferin and light. Interestingly, while the
catalytic conversion (activation) of 4b to 4a in water produces multiple products, the presence of biological
nucleophiles such as thiols prevents byproduct formation and provides
almost exclusively luminophore 4a. Our studies show that
precatalyst 2 activates 4b extracellularly,
exhibits low toxicity at concentrations relevant to catalysis, and
is comparably effective in two different cell lines. This proof of
concept study shows that precatalyst 2 is a promising
lead for bioorthogonal catalytic activation of pro-probes and, by
analogy, similarly activatable pro-drugs. More generally, this study
provides an analytical method to measure abiological catalytic activation
of pro-probes and, by analogy with our earlier studies on pro-Taxol,
similarly activatable pro-drugs in real time using a coupled biological
catalyst that mediates a bioluminescent readout, providing tools for
the study of imaging signal amplification and of targeted therapy.
Collapse
Affiliation(s)
- Hsiao-Tieh Hsu
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| | - Brian M Trantow
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| | - Robert M Waymouth
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| | - Paul A Wender
- Department of Chemistry and ‡Department of Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| |
Collapse
|
48
|
|
49
|
Abstract
Daphnanes and tiglianes are diterpenes with a shared tricyclic 5-7-6 ring system. Many members exhibit significant biological activities often associated with protein kinase C signaling. Many of these natural products (~100) have a C6-C7 α-epoxide whose influence on biological activity is little studied. Using the more readily available phorbol ester PDBu as a test substrate, we report an efficient, and potentially general, α-epoxidation method based on a vanadium-catalyzed asymmetric epoxidation with bishydroxamic acid (BHA) ligands.
Collapse
Affiliation(s)
- Pierre-Luc Boudreault
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, USA
| | - Jennifer K. Mattler
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, USA
| | - Paul A. Wender
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, USA
| |
Collapse
|
50
|
Abstract
![]()
New reactions and reagents that allow
for multiple bond-forming
events per synthetic operation are required to achieve structural
complexity and thus value with step-, time-, cost-, and waste-economy.
Here we report a new class of reagents that function like tetramethyleneethane
(TME), allowing for back-to-back [4 + 2] cycloadditions, thereby amplifying
the complexity-increasing benefits of Diels–Alder and metal-catalyzed
cycloadditions. The parent recursive reagent, 2,3-dimethylene-4-trimethylsilylbutan-1-ol
(DMTB), is readily available from the metathesis of ethylene and THP-protected
4-trimethylsilylbutyn-1-ol. DMTB and related reagents engage diverse
dienophiles in an initial Diels–Alder or metal-catalyzed [4
+ 2] cycloaddition, triggering a subsequent vinylogous Peterson elimination
that recursively generates a new diene for a second cycloaddition.
Overall, this multicomponent catalytic cascade produces in one operation
carbo- and heterobicyclic building blocks for the synthesis of a variety
of natural products, therapeutic leads, imaging agents, and materials.
Its application to the three step synthesis of a new solvatochromic
fluorophore, N-ethyl(6-N,N-dimethylaminoanthracene-2,3-dicarboximide) (6-DMA), and
the photophysical characterization of this fluorophore are described.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, United States
| | - Matthew S Jeffreys
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, United States
| | - Andrew G Raub
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, United States
| |
Collapse
|